News & Media

Take a closer look at what we’re doing across Teva worldwide

Our latest news

Teva Releases Q2 2026 Aide Memoire

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET

Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy 

Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea

Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®

Teva to Present at the Goldman Sachs Global Healthcare Conference

The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults

Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
See all news items

Discover the world of Teva

Follow our latest feature stories with news and views from across our global organization

Discover more

Media Resources

at the office

Media Inquiries

Contact our corporate communications.
Learn more

Media Kit

Files and resources for media use only
Download Teva Media Kit

Financial Reports

View Teva financial news on our global website.
Learn more

Connect with us

Teva Social Media Guidelines.
Learn more